| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
ALR2-IN-9 (compound 5N-D) (2.5-10 μM, 24 hours) can improve the functional damage of human lens epithelial cells (HLECs) caused by hyperglycemia and reduce their ROS levels[1]. ALR2-IN-9 (10 μM, 24 hours) protects HLECs from hyperglycemia-induced damage by activating the PI3K/Akt pathway and reverses the hyperglycemia-induced decrease in Nrf2, HO-1 and NQO-1 gene levels[1]. ALR2-IN-9 (10 μM, 1 hour) shows strong antioxidant efficacy by significantly attenuating the CuSO4-induced increase in ROS levels in zebrafish larvae[1]. ALR2-IN-9 (0.2% and 0.4% wt%, 8 days) can prolong the mean lifespan of Caenorhabditis elegans under oxidative stress, increase SOD and CAT activities, and reduce MDA levels[1]. ALR2-IN-9 (0.4% wt%, 8 days) can reduce ROS levels in nematodes, reverse the H2O2-mediated inhibition of AKT-1, SIR-2.1, DAF-16 and AGE-1 gene expression, and further enhance the H2O2-induced upregulation of SKN-1 and PMK-1 gene expression [1].
|
|---|---|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HLECs Tested Concentrations: 2.5, 5.0, and 10 μM Incubation Duration: 24 h Experimental Results: Reversed this hyperglycemia-induced impairments, restoring cell viability to 85.2 % at the dose of 10 μM. Western Blot Analysis[1] Cell Types: HLECs Tested Concentrations: 10 μM Incubation Duration: 24 h Experimental Results: Significantly increased the P-PI3K/PI3K and P-Akt/Akt ratios, compared to the high glucose group. Failed to activate both PI3K and Akt in the presence of the specific PI3K inhibitor LY294002. |
| References |
| Molecular Formula |
C25H28N4O6
|
|---|---|
| Molecular Weight |
480.51
|
| CAS # |
2135481-84-2
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0811 mL | 10.4056 mL | 20.8112 mL | |
| 5 mM | 0.4162 mL | 2.0811 mL | 4.1622 mL | |
| 10 mM | 0.2081 mL | 1.0406 mL | 2.0811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
